Avadel Pharmaceuticals PLC. (AVDL) Insider Purchases $46,800.00 in Stock
Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) insider Phillandas T. Thompson bought 5,000 shares of the firm’s stock in a transaction on Wednesday, September 13th. The stock was bought at an average cost of $9.36 per share, for a total transaction of $46,800.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link.
Shares of Avadel Pharmaceuticals PLC. (NASDAQ AVDL) traded up 4.19% during mid-day trading on Wednesday, hitting $11.20. 123,837 shares of the stock traded hands. Avadel Pharmaceuticals PLC. has a one year low of $8.14 and a one year high of $13.25. The stock has a 50 day moving average price of $9.30 and a 200-day moving average price of $9.78. The company has a market cap of $448.94 million, a P/E ratio of 12.17 and a beta of 1.47.
Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $0.19 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.05 by $0.14. The firm had revenue of $46.30 million for the quarter, compared to analyst estimates of $45.17 million. Avadel Pharmaceuticals PLC. had a net margin of 21.13% and a return on equity of 29.84%. The company’s revenue was up 19.0% compared to the same quarter last year. On average, analysts forecast that Avadel Pharmaceuticals PLC. will post $1.16 earnings per share for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in AVDL. PNC Financial Services Group Inc. raised its stake in shares of Avadel Pharmaceuticals PLC. by 2,484.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 10,956 shares of the company’s stock valued at $121,000 after acquiring an additional 10,532 shares during the period. US Bancorp DE acquired a new position in shares of Avadel Pharmaceuticals PLC. during the 1st quarter valued at $121,000. Sei Investments Co. lifted its holdings in shares of Avadel Pharmaceuticals PLC. by 29.5% during the 2nd quarter. Sei Investments Co. now owns 12,726 shares of the company’s stock valued at $140,000 after acquiring an additional 2,900 shares in the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in Avadel Pharmaceuticals PLC. during the 2nd quarter worth $181,000. Finally, State of Tennessee Treasury Department purchased a new stake in Avadel Pharmaceuticals PLC. during the 2nd quarter worth $194,000. 69.09% of the stock is owned by institutional investors.
A number of research analysts have commented on AVDL shares. Ladenburg Thalmann Financial Services upped their price target on Avadel Pharmaceuticals PLC. from $27.00 to $30.00 in a research note on Thursday, September 7th. Zacks Investment Research upgraded Avadel Pharmaceuticals PLC. from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Monday, July 17th. Langenberg & Company reiterated a “buy” rating and issued a $30.00 price objective (up previously from $27.00) on shares of Avadel Pharmaceuticals PLC. in a report on Thursday, September 7th. Finally, Roth Capital set a $15.00 target price on Avadel Pharmaceuticals PLC. and gave the stock a “buy” rating in a research note on Wednesday, August 9th.
About Avadel Pharmaceuticals PLC.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.
Receive News & Ratings for Avadel Pharmaceuticals PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.